Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA.
ELISA
Mass spectrometry
Nivolumab
Pharmacokinetics
Journal
Talanta
ISSN: 1873-3573
Titre abrégé: Talanta
Pays: Netherlands
ID NLM: 2984816R
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
received:
05
08
2020
revised:
06
11
2020
accepted:
09
11
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
15
5
2021
Statut:
ppublish
Résumé
Nivolumab is a fully human immunoglobulin G4 used for the treatment of several advanced solid cancers as immune checkpoint inhibitors. There are some challenges for the quantification of mAb in plasma because IgG are present intrinsically in complex biologic matrices and this determination must be based on reliable, selective, and accurate analytical methods. This study described two validated methods carried out in two separate laboratories, one developed with a triple quadrupole tandem mass spectrometry (LC-MS/MS) and the other with high resolution mass spectrometry with an orbitrap system (LC-MS/HRMS). Both methods used full-length stable isotope-labeled nivolumab-like (Arginine
Identifiants
pubmed: 33379098
pii: S0039-9140(20)31180-2
doi: 10.1016/j.talanta.2020.121889
pii:
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121889Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.